ZTS
Zoetis
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 5
Sell signal 1
dividend princes
consensus rating "Buy"
MACD Golden Cross
Revenue Beats Expectation
Low Beta
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ZTS
Zoetis Inc.
A world's leading animal health medicines and vaccines developer with a focus on livestock and companion animals
10 Sylvan Way, Parsippany, New Jersey 07054
Production and development of pet health drug products and vaccines
Zoetis, Inc. was founded in July 2012 in Delaware, USA. Zoetis is a global leader in the animal health industry, focusing on the discovery, development, manufacturing and commercialization of drugs, vaccines, diagnostic products and services, biological devices, genetic testing and precision animal health.
Company Financials
EPS
ZTS has released its 2024 Q4 earnings. EPS was reported at 1.40, versus the expected 1.34, beating expectations. The chart below visualizes how ZTS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ZTS has released its 2024 Q4 earnings report, with revenue of 2.32B, reflecting a YoY change of 4.70%, and net profit of 581.00M, showing a YoY change of 11.09%. The Sankey diagram below clearly presents ZTS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
